FDA approves Gloucester’s drug for rare skin cancer


Gloucester Pharmaceuticals received FDA approval for Istodax, a small-molecule treatment for cutaneous T-cell lymphoma. CEO Alan Colowick said the biotech startup plans to introduce the drug in January.  The Boston Globe

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s